Regeneron Pharmaceuticals: A Top Biotechnology Pick with 59.5% Upside Projection
Regeneron Pharmaceuticals Inc (REGN) is currently in the spotlight with a strong bullish projection. Analysts have set an average 12-month target price…
Browse research
Author: Muzzammil Ahmad
Muzzammil is a content writer at Stock Target Advisor. He has been writing stock news and analysis at Stock Target Advisor since 2023 and has worked in the financial domain in various roles since 2020. He has previously worked on an equity research firm that analyzed companies listed on the stock markets in the U.S. and Canada and performed fundamental and qualitative analyses of management strength, business strategy, and product/services forecast as indicated by major brokers covering the stock.
H.G. Infra Engineering: India’s Rising Star with a 42% Stock Upside Forecast
H.G. Infra Engineering Limited (HGINFRA: NSE) stands out as a compelling investment in the Engineering & Construction sector. Backed by robust fundamentals,…
Stingray Group Inc: Analysts Forecast 26% Upside Opportunity
Stingray Group Inc (RAY-A: CA) is turning heads in the broadcasting sector with its impressive financial achievements and growth projections. The company…
Addex Therapeutics Q3 2024 Earnings Preview: What Investors Need to Know
Addex Therapeutics Ltd (ADXN), a clinical-stage biopharmaceutical company specializing in innovative treatments for neurological disorders, is set to release its official Q3…
Global Blue Group Ltd Q2 Earnings Preview: Key Insights and Analyst Predictions
The financial community eagerly anticipates Global Blue Group Holding Ltd (GB) Q2 earnings report, expected on November 22, 2024. Analysts predict flat…